DANIMER SCIENTIFIC, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8049 USD | -0.79% |
|
+3.82% | -21.09% |
| 04-22 | Danimer Scientific Announces $20 Million Asset-Based Revolving Credit Facility | CI |
| 04-10 | North American Morning Briefing : Traders Await -2- | DJ |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,015 | 854.9 | 181.5 | 104.1 | 91.95 | - | - |
| Enterprise Value (EV) 1 | 1,694 | 829.7 | 181.5 | 104.1 | 91.95 | 91.95 | 91.95 |
| P/E ratio | - | -13.1 x | -1.01 x | -0.67 x | -0.88 x | -1.32 x | -1.39 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 42.6 x | 14.6 x | 3.41 x | 2.23 x | 1.17 x | 0.65 x | 0.41 x |
| EV / Revenue | 42.6 x | 14.6 x | 3.41 x | 2.23 x | 1.17 x | 0.65 x | 0.41 x |
| EV / EBITDA | -626 x | -37.9 x | -4.03 x | -2.67 x | -3.11 x | 17.3 x | 3.99 x |
| EV / FCF | -38.7 x | -3.44 x | -0.8 x | -1.39 x | -1.1 x | -0.39 x | - |
| FCF Yield | -2.58% | -29.1% | -125% | -72% | -90.8% | -254% | - |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 85,725 | 100,344 | 101,389 | 102,035 | 114,241 | - | - |
| Reference price 2 | 23.51 | 8.520 | 1.790 | 1.020 | 0.8049 | 0.8049 | 0.8049 |
| Announcement Date | 29/03/21 | 28/02/22 | 28/03/23 | 20/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 47.33 | 58.75 | 53.22 | 46.7 | 78.27 | 142 | 221.9 |
| EBITDA 1 | -3.218 | -22.58 | -44.99 | -38.99 | -29.54 | 5.317 | 23.07 |
| EBIT 1 | -11.96 | -99.47 | -187.4 | -125.6 | -67.48 | -34.31 | -23.1 |
| Operating Margin | -25.28% | -169.32% | -352.2% | -268.99% | -86.22% | -24.16% | -10.41% |
| Earnings before Tax (EBT) 1 | - | -73.34 | -180.6 | -155.2 | -105.3 | -74.82 | -73.2 |
| Net income 1 | - | -60.11 | -179.8 | -155.5 | -111.1 | -74.82 | -73.2 |
| Net margin | - | -102.31% | -337.78% | -332.92% | -141.99% | -52.68% | -32.99% |
| EPS 2 | - | -0.6500 | -1.780 | -1.520 | -0.9100 | -0.6100 | -0.5800 |
| Free Cash Flow 1 | -52.06 | -248.4 | -226.3 | -74.95 | -83.49 | -234 | - |
| FCF margin | -110% | -422.77% | -425.28% | -160.49% | -106.67% | -164.76% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 29/03/21 | 28/02/22 | 28/03/23 | 20/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 13.37 | 17.73 | 14.74 | 12.7 | 10.45 | 15.32 | 11.93 | 12.86 | 10.95 | 10.9 | 10.73 | 12.45 | 14.97 | 24.26 | 28.06 |
| EBITDA 1 | -7.353 | -10.18 | -10.6 | -12.87 | -12.94 | -8.569 | -8.852 | -10.22 | -9.252 | -10.67 | -10.12 | -9.182 | -5.998 | -5.138 | -1.467 |
| EBIT 1 | -31.83 | -35.28 | -30.69 | -32.12 | -94.91 | -29.72 | -32.23 | -31.12 | -31.24 | -31.03 | -19.88 | -18.95 | -15.8 | -15.01 | -11 |
| Operating Margin | -238.12% | -199% | -208.16% | -252.85% | -908.37% | -193.94% | -270.22% | -241.9% | -285.34% | -284.7% | -185.29% | -152.17% | -105.53% | -61.89% | -39.21% |
| Earnings before Tax (EBT) 1 | -3.598 | -14.26 | -26.68 | -30.68 | -95.11 | -28.09 | -36.73 | -39.3 | -39.69 | -39.43 | -28.55 | -27.62 | -24.9 | -24.21 | -20.73 |
| Net income 1 | 7.825 | -12.45 | -26.39 | -30.44 | -94.88 | -28.05 | -36.64 | -39.24 | -40.16 | -39.43 | -28.55 | -27.62 | -24.9 | -24.21 | -20.73 |
| Net margin | 58.53% | -70.21% | -178.97% | -239.67% | -908.08% | -183.05% | -307.22% | -305.02% | -366.82% | -361.78% | -266.09% | -221.79% | -166.33% | -99.79% | -73.88% |
| EPS 2 | 0.0800 | -0.1200 | -0.2600 | -0.3000 | -0.9400 | -0.2800 | -0.3600 | -0.3800 | -0.3900 | -0.3900 | -0.2633 | -0.2367 | -0.2100 | -0.2033 | -0.1733 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 15/11/21 | 28/02/22 | 10/05/22 | 09/08/22 | 08/11/22 | 28/03/23 | 10/05/23 | 08/08/23 | 14/11/23 | 20/03/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | 321 | 25.2 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -52.1 | -248 | -226 | -74.9 | -83.5 | -234 | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share 2 | - | - | -0.6100 | -0.4600 | -0.9000 | -2.800 | - |
| Capex 1 | - | 185 | 164 | 27.7 | 8.99 | 203 | 151 |
| Capex / Sales | - | 315.6% | 309.08% | 59.28% | 11.48% | 142.7% | 68.06% |
| Announcement Date | 29/03/21 | 28/02/22 | 28/03/23 | 20/03/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
0.8049
USD
Average target price
1.51
USD
Spread / Average Target
+87.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.09% | 91.95M | |
| +4.47% | 40.29B | |
| -25.15% | 20.6B | |
| -14.52% | 13.21B | |
| -13.48% | 9.66B | |
| -8.75% | 9.69B | |
| -4.50% | 6.61B | |
| +3.01% | 6.42B | |
| -30.31% | 5.29B | |
| -21.00% | 3.3B |
- Stock Market
- Equities
- DNMR Stock
- Financials Danimer Scientific, Inc.
